Table 1.
Open trials incorporating primary proteomic endpoints.a
| Trial Name | Primary Investigator | Trial Number | Primary Endpoint | Inclusion Criteria | Status |
|---|---|---|---|---|---|
| A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse | Kohn, E.C. | NCT00119353 | Serum proteomic profile with direct comparison to CA125 and creation of a serum repository | Histologically confirmed ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer in first complete remission | Closed to Accrual |
| ACT: Analyzing the Composition of Tears to Identify Cancer (Breast, Ovarian, Colon) | Klimberg, V.S. | NCT00574678 | This study will further evaluate the use of tumor markers (substances in body fluids that may be elevated as a consequence of certain diseases or conditions) in the diagnosis of breast and/or other cancers. | - Female or male, 18–100 years old with newly diagnosed tumor with some part of the amss still present | Currently recruiting |
| Whole Blood Collection Protocol For Ovarian Assay Clinical Trial In Women With Ovarian Tumors | Ueland, F., and Fung, E. | NCT00436189 | Evaluation of OvaRl test in patients with an ovarian mass. | - Subject is female and age 18 years or older with a documented adnexal tumor with planned surgical intervention | Completed |
| Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer | Hanash, S.M. | NCT00900094 | Identification of tumor antigens, secreted proteins in tissue and fluid samples and early detection markers | - Scheduled to undergo primary surgical resection or first debulking surgery (prior to any anticancer treatment) for suspected or newly diagnosed cancer, and metastatic or unresectable cancer of multiple cancer types including epithelial ovarian cancer | Open but not recruiting |
| Proteomic Analysis of Serology and Peptides Presented on the HLA Complex of Breast, Ovarian, Colon, Rectal, Gastric and Pancreatic Adenocarcinoma | Ashkenazi, I. | NCT00419627 | Evaluation of proteins presented by the HLA complex of solid tumors. | Patients with adenocarcinoma of breast, colon, rectum, ovary, stomach, pancreas | Open but not recruiting |
| Urine PGE-M in Ovarian Cancer | Rao, G.G. | NCT00900523 | Measurement of urine PGEM Correlation of urine PGEM with tissue COX-1 and COX-2 levels | Diagnosis of known or suspected ovarian cancer | Open but not recruiting. |
| Pelvic Mass Study to Develop Serum Proteomic Profiles (SIGNATURES) for Epithelial Ovarian Cancer Diagnosis and Prognosis | Kohn, E.C., Khleif, S.N., Copeland, L.J. | NCT00238342 | Generate and validate a serum proteomic profile that can predict the presence of invasive ovarian epithelial cancer. | Patients with an abnormal pelvic mass by physical examination or imaging test planning to undergo surgical evaluation within the next 3 weeks | Open but not recruiting |
a
Trial information from clinicaltrials.gov database filtered for search terms Ovarian Cancer and/or Proteomics with a proteomics endpoint as a primary endpoint.